ValuentumAd

Official PayPal Seal
Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Oct 23, 2017
In August, We “Cut” Position in Hasbro in Dividend Growth Newsletter Portfolio
We still have a small “position” in the emerging licensing giant in the Dividend Growth Newsletter portfolio, having removed 75% of the “stake” in August.
Oct 23, 2017
Restasis Patent Protection Weighing on Shares of Allergan
Image Source: Allergan. We have witnessed numerous examples over the years of biotech/pharma companies selling-off over fears of the length of patent protection on an essential product. The concern is well-founded--if the company relies on the product for a significant portion of sales, it may be challenging to replace, especially if the clinical pipeline is relatively bereft of viable next-generation products. We believe the recent sell-off in the shares of Allergan may now be wholly factoring in the loss of patent protection of one of its core assets in Restasis, and the equity may not be getting enough credit for its highly diversified revenue stream.
Oct 15, 2017
Dividend Increases/Decreases for the Week Ending October 13
Let's take a look at companies raising/lowering their dividends this week.
Oct 5, 2017
The Bull Case for Airline Stocks?
Image Source: BriYYZ. Warren Buffett has famously said that airline stocks are horrible long-term investments, but his vast portfolio now owns a number of airlines. What’s the bull case for owning these capital-intensive, cyclical and often boom-and-bust stocks?
Oct 5, 2017
Competitive Pressures Not Going Away for Teva
Image Source: Mylan. The end of the patent life of a lucrative product can often lead to significant legal strife as aspiring biosimilar equivalents jockey for exclusivity. We have found the recent aggressive move by Mylan noteworthy in our ongoing coverage of Teva’s recent struggles. On a separate but related note, the settlement between Amgen and Abbvie underscores the volatile nature of maneuvers conducted in order to extend the patent life of a highly successful product.
Oct 5, 2017
The Legal Battle Between Regeneron and Amgen Heats Up
Image Source: Regeneron. The legal battle between two of the titans of the biotech world heated up further with a recent ruling overturning the injunction of a critical asset. We are updating our thesis in light of current events.
Sep 24, 2017
Dividend Increases/Decreases for the Week Ending September 22
Let's take a look at companies raising/lowering their dividends this week.
Sep 22, 2017
Microsoft’s Dividend Growth Doesn’t Disappoint
Image Source: Valuentum. Microsoft has been one of our favorite dividend growth ideas. On September 19, the company raised its dividend nearly 8%, to $0.42 per share on a quarterly basis.
Sep 13, 2017
Earnings Snapshot: Cracker Barrel’s Hidden 5%+ Dividend Yield
Cracker Barrel is holding its share-price uptrend nicely. The company is one of our favorite restaurants thanks in part to its differentiated niche and country store concept. Special dividend payouts make it a hidden income gem, in our view.
Sep 9, 2017
Fair Value Estimates of Stocks In Our Coverage Universe
In this article, use the download to view the fair value estimates of companies in our coverage universe.


The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.